TONIX PHARMACEUTICALS HOLDING CORP (TNXP)
Health Care · Biopharmaceuticals · NASDAQ
A commercial-stage biopharmaceutical company focused on CNS, immunology, and infectious disease therapies, headlined by its FDA-approved fibromyalgia treatment, TONMYA.
What TONIX PHARMACEUTICALS HOLDING CORP does
Tonix Pharmaceuticals is a fully-integrated biopharmaceutical company that commercializes and develops therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its commercial portfolio includes TONMYA for fibromyalgia, as well as Zembrace SymTouch and Tosymra for acute migraine. The company also maintains a diverse development pipeline of clinical and preclinical candidates spanning multiple therapeutic areas.
Recent developments
In June 2026, the company commenced the HORIZON study, a Phase 2 trial for TNX-102 SL as a monotherapy for major depressive disorder. Tonix also secured a managed care partnership in May 2026 providing access to approximately 35 million U.S. commercial lives.
From TONIX PHARMACEUTICALS HOLDING CORP's filing of 2026-08-10.
Themes: CNS disorders, fibromyalgia, migraine treatment, immunology, infectious diseases, rare diseases, vaccine development, non-opioid analgesics
Fundamentals
- Price$5.78 as of 2026-10-20 close
- Market cap$99M as of 2026-08-07 (share count; price 2026-10-20)
- 1-year return-70.9% 2025-10-20 close $19.84 → 2026-10-20 close $5.78
- P/En/a negative earnings
- Net margin-946.2% FY2025, SEC XBRL
- ROE-50.6% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue growth (YoY)+29.9% FY2025, SEC XBRL
- Revenue CAGR (3y)+29.9% SEC XBRL
- Beta1.07 as of 2026-09-02
- Last reported earnings2026-10-15 SEC EDGAR Form 8-K (Item 2.02)
How TNXP compares in its sector
- net profit marginbottom 25% 430 covered Health Care peers, as of 2026-09-02
- operating marginbottom 25% 417 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $14M | -$43M | -$41M | -$2.44 | -$42M† | $587000† |
| Q1 FY2026 2026-03-31 | $7M | -$42M | -$40M | -$2.93 | -$42M | $2M |
| Q4 FY2025 2025-12-31 | $5M† | -$48M† | -$47M† | -$4.15† | -$40M† | $2M† |
| Q3 FY2025 2025-09-30 | $3M | -$33M | -$32M | -$3.59 | -$29M† | $962000† |
| Q2 FY2025 2025-06-30 | $2M | -$28M | -$28M | -$3.86 | -$15M† | $527000† |
| Q1 FY2025 2025-03-31 | $2M | -$16M | -$17M | -$2.84 | -$17M | $6000 |
| Q4 FY2024 2024-12-31 | $3M† | -$22M† | -$22M† | $289.57† | -$15M† | $3000† |
| Q3 FY2024 2024-09-30 | $3M | -$16M | -$14M | -$22.68 | -$19M† | $9000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$176M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How TONIX PHARMACEUTICALS HOLDING CORP looks technically
TONIX PHARMACEUTICALS HOLDING CORP (TNXP) is trading 55.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 248 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 57, with sellers in control. Momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 16, in oversold territory (below 30). It made a new 20-day low about 2 trading days ago. It is 4.2% above its 52-week low (its lowest price of the past year).
Trend
7
| Distance from the 200-day | it is trading 55.1% below its 200-day average, the long-term trend line — a long-term downtrend | -55.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $10.69 | $10.69 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $12.89 | $12.89 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 50 calendar days ago — the swings before that are what the structure reading is measured on | 50 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 248 trading days ago — a "death cross", a bearish long-term signal | 248 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 57, with sellers in control | 56.8 |
Momentum
3
| 14-day RSI | momentum is beaten down — its 14-day RSI (a 0–100 momentum gauge) is 16, in oversold territory (below 30) | 15.5 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($5.54 to $9.69) — its "stochastic" reading is 6 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 5.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 32 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $20.58 | $20.58 |
|---|---|---|
| From the 52-week high | it is 71.9% below its 52-week high (its highest price of the past year) | -71.9% |
| Above the 52-week low | it is 4.2% above its 52-week low (its lowest price of the past year) | +4.2% |
| Below the 52-week high | it is 71.9% below its highest point of the past year | 71.9% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $19200000000.00 (set on 2012-05-10) | $19200000000.00 |
| Given back of the 52-week move | over the past year its closes ranged ($5.73 to $20.35), and it has recovered essentially none of its fall from last year’s high — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $14.77 to $15.23. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.3% |
| From the all-time high | it is 100.0% below its all-time high | -100.0% |
| Nearest price level | it is trading 100.6% below a resistance level at $11.60 — a price it turned at twice since 2026-03-30, most recently on 2026-06-26. Since 2024-10-21 it has 0 such levels below the current price and 10 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +100.6% |
| All-time low | its lowest closing price on record is $5.54 (set on 2026-10-20) | $5.54 |
| Above the all-time low | it is 4.2% above its all-time low | +4.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.5908 between its high and its low — about 10.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.5908 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $4.80 and $11.03 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $4.80 – $7.91 – $11.03 |
| Typical daily range (% of price) | its price moves about 10.2% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 10.2% |
| Stretch from the 200-day average | it is trading 12.0 daily ranges below its 200-day average price (55.1% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 12.0 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.94× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-20 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Gap filled | a 2.0% gap up opened on 2026-09-17 has been "filled" 23 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 23 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 47.8 percentage points (the stock lost 46.8% while the market gained 1.0%) | -47.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 51.0 percentage points (the stock lost 47.4% while the market gained 3.6%) | -51.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 68.2 percentage points (the stock lost 59.7% while the market gained 8.5%) | -68.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 85.4 percentage points (the stock lost 70.9% while the market gained 14.6%) | -85.4% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: its RSI momentum gauge is oversold (a beaten-down reading), near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 52% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 15.0% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -51.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 53% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $12.21 — a volume-weighted average of daily closes over 201 sessions, not a true tick-by-tick VWAP. | -52.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 40% below the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is under water. That average is $9.63 — a volume-weighted average of daily closes over 51 sessions, not a true tick-by-tick VWAP. | -40.0% |
Price levels it has turned at before
TNXP last closed at $5.78 on 2026-10-20. Since 2024-10-21 it has turned at 0 prices below its last close and 10 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $11.60 | Resistance | 100.6% above the last close | turned there twice · 2026-03-30 to 2026-06-26 |
| $13.15 | Resistance | 127.5% above the last close | turned there three times · 2026-03-06 to 2026-07-08 |
| $13.63 | Resistance | 135.9% above the last close | turned there twice · 2025-11-25 to 2026-06-25 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Oversold (14-day RSI below 30) · Pulled back from the 12-month high · Broke down to a new 20-day low · Near the all-time low | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$44.50 range $22.00 – $65.00; median $45.50
Analyst estimates, as of 2026-10-20. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for TNXP
- Consensus EPS estimate-$2.33 next reporting period, as of 2026-10-20
- Estimate change, 30 days$0.00 from -$2.33, on 2026-09-15, 35-day window
- Readings revised upward11% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of operating losses with no guarantee of achieving future profitability.","High dependence on the successful commercialization of TONMYA for business viability.","Need for significant additional capital to fund ongoing operations and development pipeline."]
What changed in the latest 10-Q
AI-assisted comparison of TNXP's 10-Q filed 2026-05-11 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- TONMYA® branding and trademark details added (newer filing uses registered trademark symbol and specifies 'Tonix Pharma Limited' ownership)
- Explicit statement that TONMYA 'was commercially launched by us in the United States on November 17, 2025' (newer filing provides specific launch date)
- Statement that company 'holds worldwide commercialization rights to TONMYA' (newer filing)
- Addition of TNX-102 SL Phase 2 study for MDD described as 'expected to commence mid-2026' with cleared Tonix IND (newer filing)
- Details about TNX-4800 field study planned for 'first half of 2027' pending FDA agreement (newer filing)
- TNX-1500 described as 'Phase 2-ready' in newer filing (older filing described planned Phase 2 study details differently)
- Addition of TNX-1300 (double-mutant cocaine esterase) with Breakthrough Therapy designation, Phase 2a completion, and 2026 FDA meeting plan (newer filing)
- Specification that TNX-2900 Phase 2 study expected to 'start...in the first quarter of 2027' (newer filing specifies Q1 vs older filing's 'second half of 2026')
- Addition of manufacturing facility details: 'Dartmouth, MA' facility 'decommissioned in 2024' with reactivation criteria (newer filing)
- Addition of TNX-1700 fusion protein program with Columbia University collaboration for gastric and colorectal cancer (newer filing)
- Addition of TNX-4900 Sigma-1 receptor antagonist licensed from Rutgers University (newer filing)
- Expansion of TNX-4200 description to include 'high lethality infections' and $34 million contract details (newer filing)
- Removed:
- Description of company as 'commercial-stage biotechnology company' changed to 'fully-integrated biopharmaceutical company' (language change, not removal)
- Reference to TNX-1500 as 'dimeric Fc-modified' removed; newer filing describes as 'Fc-modified' without 'dimeric' (newer filing)
- Removal of statement that TNX-1500 is 'being developed for...the treatment of autoimmune diseases' (narrower scope in newer filing)
- Removal of MGH collaboration details for TNX-1500 Phase 2 study (replaced with different development status in newer filing)
- Removal of contingent language for TNX-1500 Phase 2 ('contingent on FDA clearance of an investigator-initiated IND and approval by the institutional review board') (newer filing)
- Removal of specific timeline 'in the second half of 2026' for TNX-2900 Phase 2 initiation; replaced with 'first quarter of 2027' (older filing)
- Removal of TNX-801 description as 'recombinant horsepox' and 'vaccine in development'; newer filing describes as 'horsepox, live virus vaccine' for 'potential vaccine' (language refinement)
- Removal of reference to TNX-4800 as 'long-acting monoclonal antibody for the seasonal prevention of Lyme Disease' and 'adaptive Phase2/3 study' language changed to 'adaptive Phase 2 field study' (newer filing)
- Removal of descriptive detail about TNX-4200 for 'prevention or treatment of infections' simplified in newer filing
- Removal of specific mention of MGH collaboration (older filing)
- Reworded:
- Pronoun change: 'members of our management team' to 'members of our management team' (no material change but grammatical consistency)
- Forward-looking statement factors reordered: older filing lists 'the ability to commercialize our approved products; substantial competition' first, newer filing reorganizes with 'our need for additional financing' and FDA risks listed differently
- TONMYA brand presentation: older filing uses 'Tonmya' (no registered trademark), newer filing uses 'TONMYA®' consistently with trademark symbol
- Business description: older 'commercial-stage biotechnology company with marketed products and a pipeline' changed to 'fully-integrated biopharmaceutical company commercializing and developing innovative therapies' (newer filing)
- TNX-102 SL description in CNS section reordered with MDD Phase 2 as expected mid-2026 launch (newer filing shifts emphasis)
- TNX-4800 description: changed from 'long-acting monoclonal antibody for the seasonal prevention' to 'anti-Borrelia OspA human monoclonal antibody for the prevention' (newer filing)
- TNX-4800 study type: changed from 'adaptive Phase2/3 study' to 'adaptive Phase 2 field study' (newer filing)
- TNX-2900 timing: changed from 'second half of 2026' to 'first quarter of 2027' (older filing dated Nov 2025 vs newer filed May 2026)
- TNX-1500 status descriptor: removed 'dimeric' specification in newer filing
- TNX-2900 intranasal oxytocin description: consistent between filings but newer filing provides different timeline
- Infectious disease portfolio description: newer filing adds substantial detail on facility ownership and decommissioning status
- Notes:
- The older filing (Nov 10, 2025) discusses TONMYA approval received in August 2025 and launch expected 'before the end of November 2025'; the newer filing (May 11, 2026) confirms launch occurred on November 17, 2025, representing passage of time rather than a content change
- Development timelines shifted between filings (e.g., TNX-2900 from H2 2026 to Q1 2027) likely due to six-month gap between filing dates and actual program progress
- Both filings are truncated at similar points ('regulatory submissions' in older, 'regu' in newer), limiting full comparison of Results of Operations section
- TNX-1300 program details (Breakthrough Therapy status, Phase 2a completion, study termination) appear only in newer filing; unclear if program existed in older period or if information was not disclosed
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
2 open-market purchases and 0 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-17. The 4 days since 2026-10-17 have not been checked yet.
- Last 90 days · read to 2026-10-172 buys ($40180) · 0 sells — 2 buying insiders
- Last 180 days · read to 2026-10-175 buys ($172308) · 0 sells — 4 buying insiders
Cluster buying: 3 different insiders reported open-market purchases (SEC code P) of TNXP within a 30-day window between 2026-06-08 and 2026-06-12. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-27. Based on Form 4 filings read through 2026-10-17; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about TNXP's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding TNXP as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 2,337,084
- Reported value $29,821,194
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about TNXP's institutional holders → See what each manager we track holds →
Short interest (FINRA)
TNXP had 2,937,499 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
TNXP had 17.1% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.9 days to cover at the same settlement.
- Reported short interest (shares) 2,937,499
- Short interest (% of shares outstanding) 17.1%
- Prior settlement (shares) 2,838,419
- Reported change 3.49%
- Days to cover (reported) 5.9
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Eli Lilly (LLY)
- Pfizer (PFE)
- AbbVie (ABBV)
- Amgen (AMGN)
- Biogen (BIIB)
- Teva Pharmaceutical Industries (TEVA)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare TNXP vs…
TONIX PHARMACEUTICALS HOLDING CORP is found in…
Frequently asked questions
What does TONIX PHARMACEUTICALS HOLDING CORP (TNXP) do?
Tonix Pharmaceuticals is a fully-integrated biopharmaceutical company that commercializes and develops therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its commercial portfolio includes TONMYA for fibromyalgia, as well as Zembrace SymTouch and Tosymra for acute migraine. The company also maintains a diverse development pipeline of clinical and preclinical candidates spanning multiple therapeutic areas.
What sector is TONIX PHARMACEUTICALS HOLDING CORP (TNXP) in?
TONIX PHARMACEUTICALS HOLDING CORP (TNXP) is classified in the Health Care sector. Its industry is Biopharmaceuticals. It trades on NASDAQ.
Who are TONIX PHARMACEUTICALS HOLDING CORP's (TNXP) competitors?
Notable peers of TONIX PHARMACEUTICALS HOLDING CORP (TNXP) include Eli Lilly, Pfizer, AbbVie, Amgen and Biogen. This peer set is informational only — not financial advice.
Is TONIX PHARMACEUTICALS HOLDING CORP (TNXP) overbought or oversold right now?
TONIX PHARMACEUTICALS HOLDING CORP (TNXP) is currently in oversold territory (its 14-day RSI is 16, below 30) (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on TNXP come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.